Profund Advisors’s Stoke Therapeutics STOK Stock Holding History

Profund Advisors’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$879K	Sell	26,985 -6,403	-19%	-$210K	0.03%	382
2025 Q4	$1.06M	Buy	+33,388	New	+$1M	0.03%	344
2025 Q3	–	Sell	-10,986	Closed	-$125K	–	1089
2025 Q2	$125K	Sell	10,986 -1,896	-15%	-$18K	﹤0.01%	952
2025 Q1	$85.7K	Sell	12,882 -266	-2%	-$2.48K	﹤0.01%	965
2024 Q4	$145K	Sell	13,148 -3,253	-20%	-$40K	0.01%	1046
2024 Q3	$202K	Buy	16,401 +1,508	+10%	+$21.4K	0.01%	1049
2024 Q2	$201K	Buy	+14,893	New	+$201K	0.01%	989

Other funds holding STOK

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Profund Advisors's STOK Position: Q1 2026 in Review

Profund Advisors reduced its Stoke Therapeutics (STOK) stake by 19% in Q1 2026, selling an estimated $210K and leaving 26,985 shares worth $879K. The position accounts for 0.03% of the portfolio, ranked #382.

Profund Advisors first reported a position in STOK in Q2 2024 and has held it in 7 quarters since. The position peaked at $1.06M in Q4 2025. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

Profund Advisors held 26,985 shares of Stoke Therapeutics worth $879K as of Q1 2026.
Profund Advisors sold 6,403 Stoke Therapeutics shares in Q1 2026, an estimated $210K.
Stoke Therapeutics made up 0.03% of Profund Advisors's portfolio in Q1 2026, its #382 holding.
Profund Advisors first reported a position in Stoke Therapeutics in Q2 2024 and has held it in 7 quarters since.
Profund Advisors's Stoke Therapeutics position peaked at $1.06M in Q4 2025.
196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.